News
Women’s Health Week Europe launches following success of SiS London
Following the success of the sold-out SiS London event in 2024, Women’s Health Week Europe has been announced—a transformative three-day summit dedicated to scaling breakthrough innovations in women’s healthcare.
Set to take place October 15-17, 2025, at London’s iconic Barbican Centre, the expanded format reflects the overwhelming industry demand for a comprehensive platform connecting founders, investors, corporations, and service providers exclusively focused on advancing women’s health solutions.
Nathan Edwards is Founder of SiS (Solve Impact Scale).
Edwards said: “What began as SiS—a focused commercial acceleration platform for innovators —has completely transformed into the largest Women’s Health event in Europe.
“The overwhelming response to SiS London 2024 demonstrated the urgent market need for a platform that brings together the entire ecosystem to accelerate growth.
“Women’s Health Week Europe represents our commitment to meeting this need while maintaining our core focus on growth-stage innovators.”
The inaugural Women’s Health Week Europe will feature:
- 400 industry leaders from across the global women’s health ecosystem
- 50 visionary speakers delivering unfiltered case studies and strategic insights, including:
-
- Mindy Simon, Co-Director, NHS Innovation Accelerator
- Charlotte O’Neill, Managing Director, Man City
- Tatum Getty, Founding General Partner, THENA Capital
- Christina Hennessey, Medical Director, Boots
- Rhiannon White, CEO, Clue
- Jenny Saft, Founder, Apryl
- 20 hours of curated networking and partnership development opportunities
- Interactive masterclasses on scaling women’s health innovations internationally
- AI-powered matchmaking via the proprietary Matchmaik.io platform
Women’s Health Week Europe builds on the proven model of creating commercial opportunities in women’s health—a sector projected to reach $50 billion by 2025.
The SiS London 2024 event catalysed multiple investment deals and strategic partnerships, demonstrating the significant business opportunity within this historically underserved segment.
The expanded format allows SiS to serve its growing community while maintaining its distinctive approach: connecting high-potential companies with the resources, partners, and capital needed to scale their solutions globally.
Join the waitlist for priority access to tickets HERE (https://event.womenshealthweek.com/europe)
For more information, visit womenshealthweek.com or contact info@sis.global
Menopause
Medichecks acquires My Menopause Centre to expand specialist hormone health services
Digital diagnostics company Medichecks has acquired specialist menopause health platform and clinic My Menopause Centre.
The deal is part of Medichecks’ move into clinical services and follows its earlier purchase of Leger Clinic, creating what the company describes as a hormone health offering for women and men across the UK.
Medichecks and My Menopause Centre will combine digital services with clinical governance. The acquisition aims to enhance Medichecks’ ability to deliver integrated testing, diagnosis and ongoing clinical support.
The combined group plans to grow its specialist hormone health services, supporting patients across the UK with clinical care throughout different stages of their hormone health journey.
Helen Marsden, co-founder of Medichecks, said: “At Medichecks, our mission is to make healthcare more accessible, evidence-based and patient-centred.
“Helen and Clare have built an outstanding, clinically credible platform that is transforming menopause care for women across the UK.
“Medichecks now owns two CQC Outstanding-rated clinics, the only clinics in their respective sectors to achieve this rating, and we are deeply committed to delivering safe, compassionate and patient-centric care.
“We’re proud to continue the founders’ legacy while supporting the next stage of growth, ensuring more women can access high-quality menopause care when they need it most.”
The CQC, or Care Quality Commission, is the independent regulator of health and social care in England.
The acquisition supports Medichecks’ plans to make hormone healthcare more accessible by delivering integrated testing, diagnosis and ongoing clinical support for patients across the UK.
Helen Normoyle, co-founder and chief executive of My Menopause Centre, said: “We set out to build something resilient, clinically credible and scalable, not just fast.
“Our mission has always been to make menopause care compassionate, accessible and grounded in evidence. Medichecks shares that vision.
“Their digital platform, commitment to clinical excellence and patient-centred care make them the ideal partner to take My Menopause Centre into its next chapter.
“This milestone reflects not only a strong product, but a remarkable team and community.
“I’m deeply proud of what we’ve built and excited to see My Menopause Centre grow further under Medichecks’ leadership.”
Menopause
Menopause specialist Haver joins Midi Health
Menopause specialist Dr Mary Claire Haver has been appointed as the first chief agewell officer at virtual care clinic Midi Health.
In the role, Dr Haver will work with Midi’s clinical team to develop the AgeWell platform, described as a proactive health model that integrates perimenopause and menopausal care with metabolic health, bone density, brain health and cardiovascular risk assessment.
The platform aims to provide preventative care targeting what the company describes as the primary drivers of female mortality and disability: heart disease, bone loss and cognitive decline.
Joanna Strober, chief executive and co-founder of Midi Health, said: “Longevity care has historically ignored women’s biology, especially during the critical windows of midlife and menopause.
“At Midi Health, we are committed to extending healthspan, not just lifespan, and making that care accessible to millions of women as a core pillar of their health.
“By collaborating with Dr Haver, we are ensuring women continue to have access to care designed for their bodies, their hormones, and their real lives.”
Dr Haver is board-certified in obstetrics and gynaecology, a Menopause Society certified practitioner, a certified culinary medicine specialist and an adjunct associate professor of obstetrics and gynaecology at The University of Texas Medical Branch.
After a career in academic medicine, Dr Haver founded The Pause Life, described as a science and education-based resource for women navigating perimenopause and the menopause transition.
Through her books, unPaused podcast and digital platform, she has provided education on midlife health.
Dr Mary Claire Haver said: “I have spent my career advocating for women to receive the science-backed, no-nonsense guidance they deserve.
“I chose to partner with Midi Health because they are the only platform with the scale and medical rigour to deliver the kind of care women deserve, regardless of their zip codes.
“Together, we are setting a new standard for proactive, preventative care that meaningfully extends both lifespan and healthspan for women.”
Events
Kate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live
Women’s Health Week USA 2026 has unveiled its first populated agenda, anchored by an opening keynote from Kate Ryder, Founder and CEO of Maven Clinic, and featuring a cross-sector lineup shaping the next phase of scale in women’s health.
You can view the full agenda here.
Taking place May 13–14, 2026, at the New York Academy of Medicine, Women’s Health Week USA brings together the full women’s health ecosystem to focus on one central question: what does it take to move women’s health from innovation to institutional scale?
Kate Ryder will open Day 1 with a keynote drawing on her experience building Maven Clinic into the world’s largest virtual clinic for women’s and family health.
Under her leadership, Maven has partnered with employers and health plans to deliver care across fertility, maternity, postpartum, paediatrics, and menopause at scale.
Her perspective sets the tone for a program centered on commercialisation, partnership, and sustainable growth.
Beyond the opening keynote, the newly released agenda reflects the sector’s growing maturity.
Across two days, the program features 70+ speakers, with representation from leading organizations including the FDA, Planned Parenthood, CVS Health Ventures, Samsung Next, NIH, WHO, and Maven Clinic.
Sessions span investment and deal flow, clinical innovation, regulation, data and technology, and market expansion, alongside dedicated pitch sessions and curated 1:1 matchmaking designed to turn insight into action.
The agenda has been built to facilitate meaningful connections across the ecosystem, with partnerships positioned as the primary driver of scale.
As women’s health continues to attract institutional capital and global attention, Women’s Health Week USA 2026 offers a clear snapshot of where the market is heading, and who is shaping it.
The full agenda is now live, with additional speakers and partners to be announced in the coming months.
View the full programme here.
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Fertility4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight3 weeks agoChina’s birth rate hits record low despite government fertility efforts





